LYEL (Lyell Immunopharma) Debt-to-Equity : 0.15 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Debt-to-Equity?

Lyell Immunopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $7.97 Mil. Lyell Immunopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $50.99 Mil. Lyell Immunopharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $382.82 Mil. Lyell Immunopharma's debt to equity for the quarter that ended in Dec. 2024 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lyell Immunopharma's Debt-to-Equity or its related term are showing as below:

LYEL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.08 Max: 0.15
Current: 0.15

During the past 6 years, the highest Debt-to-Equity Ratio of Lyell Immunopharma was 0.15. The lowest was 0.07. And the median was 0.08.

LYEL's Debt-to-Equity is ranked worse than
50.25% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs LYEL: 0.15

Lyell Immunopharma Debt-to-Equity Historical Data

The historical data trend for Lyell Immunopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Debt-to-Equity Chart

Lyell Immunopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.07

0.08

0.10

0.15

Lyell Immunopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.10	0.09	0.09	0.10	0.15

Competitive Comparison of Lyell Immunopharma's Debt-to-Equity

For the Biotechnology subindustry, Lyell Immunopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyell Immunopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Lyell Immunopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lyell Immunopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.974	+	50.994)	/	382.824
	=	0.15

Lyell Immunopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.974	+	50.994)	/	382.824
	=	0.15

Lyell Immunopharma (NAS:LYEL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lyell Immunopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyell Immunopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, South San Francisco, CA, USA, 94080

Website

https://www.lyell.com

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Executives

Charles W. Newton	officer: Chief Financial Officer	46 FREDRICK AVENUE, ATHERTON CA 94027
Lynn Seely	director	501 2ND STREET, SUITE 211, SAN FRANCISCO CA 94107
Richard Klausner	director, officer: Executive Chairman	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang	officer: Chief Business Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson	officer: Chief Legal Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson	officer: Chief Medical Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee	officer: Chief Scientific Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans	director, officer: Chief Executive Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill	officer: Chief Technical Ops. Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631